471 patents
Page 12 of 24
Utility
Therapeutic Antibodies and Their Uses
20 Jan 22
The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof.
JAMES REASONER APGAR, ANDREA THERESE HOOPER, MALGORZATA AGNIESZKA NOCULA-LUGOWSKA, LEI WU
Filed: 16 Jul 21
Utility
Compounds and Methods of Use
6 Jan 22
This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity.
Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
Filed: 22 May 21
Utility
Aminopyrimidinyl Derivatives
6 Jan 22
Brian Stephen GERSTENBERGER, Wenhua JIAO, Manjinder Singh LALL, Ricardo LIRA, Mark Edward SCHNUTE
Filed: 30 Jun 21
Utility
Immunogenic Compositions and Uses Thereof
6 Jan 22
The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant.
Annaliesa Sybil Anderson, Leena Shriram Bagle, Amardeep Singh Bhupender Bhalla, Miguel Angel Garcia, Lei Hu, Lakshmi Khandke, Avvari Krishna Prasad, Cindy Xudong Yang
Filed: 14 Sep 21
Utility
Binding Molecules to the Human OX40 Receptor
6 Jan 22
The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
Jing MIN, Yanli WU, Rory F. FINN, Barrett R. THIELE, Wei LIAO, Ronald P. GLADUE, Arvind RAJPAL, Timothy J. PARADIS, Peter BRAMS, Brigitte DEVAUX, Yi WU, Kristopher TOY, Heidi N. LEBLANC, Haichun HUANG
Filed: 13 Jul 21
Utility
Antibodies to Coagulation Factor Xia and Uses Thereof
30 Dec 21
In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided.
Thomas MIKITA, Lauren K. ELY, Huilan GAO, Yun KIM, Isaac J. RONDON, Tovo DAVID, Shaun R. COUGHLIN
Filed: 23 Jun 21
Utility
Immunogenic Compositions for Use in Pneumococcal Vaccines
23 Dec 21
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates.
David Cooper, Kathrin Ute Jansen, Michael William Pride
Filed: 1 Sep 21
Utility
Dosage Regimen for TFPI Antagonists
23 Dec 21
Dosing regimens for the treatment of coagulation disorders using anti-TFPI antibodies are provided.
Tong Zhu, Steven Arkin, Matthew H. Cardinal, Chay Ngee Lim, Satyaprakash Nayak
Filed: 9 Oct 19
Utility
Combination for Treating Cancer
16 Dec 21
Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased cytokine agonist, and an anti-androgen or a pharmaceutically acceptable salt thereof.
Christoffel Hendrik Boshoff, Rossano Cesari, Cristian Massacesi, Deborah Charych
Filed: 4 Nov 19
Utility
PYRROLO[2,3-D]PYRIMIDINE Tosylate Salt, Crystalline Form Thereof and Manufacturing Process and Intermediates Thereto
16 Dec 21
The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical composition containing the same, as well as preparations and uses thereof.
Brian Matthew SAMAS, Yong TAO, Douglas James Critcher, David Sydney Bernard Daniels, Kevin Paul Girard, Gregory Scott Goeken, Peter Robert Rose
Filed: 21 Oct 19
Utility
Polymorph Form of a Monophosphate Hydrate Salt of a Known Tetrahydroisoquinoline Derivative
16 Dec 21
This invention relates to crystalline (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol monophosphate hydrate, and to compositions and therapeutic uses thereof.
Brian Samas, Wesley Clark
Filed: 20 Jan 20
Utility
Crystalline Forms of Lorlatinib Maleate
16 Dec 21
This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile (lorlatinib) maleate.
Klimentina Dimitrova Pencheva
Filed: 1 Jul 21
Utility
Protein Tyrosine Phosphatase Inhibitors
9 Dec 21
James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John Peter FISCHER, Ronald Jay HINKLIN, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
Filed: 17 Oct 19
Utility
Methods and Combination Therapy to Treat Biliary Tract Cancer
9 Dec 21
This invention relates to a method of treating biliary tract cancer by administering to a patient in need thereof, over a period of time, therapeutic agents comprising a MEK inhibitor or a pharmaceutically acceptable salt thereof, and a fluoropyrimidine-containing therapy, to a patient in need thereof.
Do-Youn Oh
Filed: 12 Feb 19
Utility
Process for the Preparation of 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE
9 Dec 21
Charles Todd EARY, Stacey SPENCER, Zack CRANE, Katelyn CHANDO, Sylvie ASSELIN, Weidong LIU, Mike WELCH, Adam COOK, Gabrielle R. KOLAKOWSKI, Andrew T. METCALF, David A. MORENO, Tony P. TANG
Filed: 13 Aug 21
Utility
Aminopyrimidinyl Compounds
2 Dec 21
Andrew FENSOME, Ariamala GOPALSAMY, Brian S. GERSTENBERGER, Ivan Viktorovich EFREMOV, Zhao-Kui WAN, Betsy PIERCE, Jean-Baptiste TELLIEZ, John I. TRUJILLO, Liying ZHANG, Li XING, Eddine SAIAH
Filed: 6 Aug 21
Utility
Dispensing Device
2 Dec 21
A device for dispensing individual doses of powder from respective pockets of a disc-shaped carrier by outwardly rupturing a lidding foil by means of pressure on an opposite side surface, the device providing individual respective deaggregation flow paths for each pocket, split airstreams allowing improved entrainment of powder, a cam mechanism for outwardly rupturing the pockets, an indexing mechanism linked to the cam mechanism and a dose counter.
Peter J. Houzego, John Kelshaw Conway, Martin Douglas Pearl, Andrew Mark Bryant
Filed: 13 Aug 21
Utility
Glycoconjugation Process
2 Dec 21
The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
Filed: 12 Aug 21
Utility
Compounds and Uses Thereof to Treat Tumors In a Subject
18 Nov 21
The present invention relates to compounds that can be used to induce immunogenic cell death (ICD).
Astrid Zimmermann, Maria Jesus Ortiz Ruiz, Heike Dahmen, Thomas Grombacher
Filed: 13 Mar 19
Utility
Novel IMIDAZO[4,5-C]QUINOLINE Derivatives As LRRK2 Inhibitors
18 Nov 21
Michael Aaron BRODNEY, Thomas Allen CHAPPIE, Jinshan Michael CHEN, Jotham Wadsworth COE, Karen Jean COFFMAN, Paul GALATSIS, Michelle Renee GARNSEY, Christopher John HELAL, Jaclyn Louise Henderson, Bethany Lyn KORMOS, Ravi G. KURUMBAIL, Luis Angel MARTINEZ-ALSINA, Martin Youngjin PETTERSSON, Matthew Richard REESE, Colin Richard ROSE, Antonia Friederike STEPAN, Patrick Robert VERHOEST, Travis T. WAGER, Joseph Scott WARMUS, Yuan ZHANG
Filed: 6 Mar 18